# Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

> **NCT00629837** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 27 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)
- **BIOLOGICAL:** Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)
- **BIOLOGICAL:** Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- **BIOLOGICAL:** Recombinant Factor VIII (Kogenate FS, BAY14-2222)

## Key facts

- **NCT ID:** NCT00629837
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** 2006-03
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2014-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00629837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00629837, "Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00629837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*